# US 2005/0032175 A1 · High affinity fusion proteins and therapeutic and diagnostic methods for use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032175 A1
- Document ID: US20050032175A1
- Status: Published application
- Kind: A1
- Application number: 10/879,994
- Filed: 2004-06-29
- Published: 2005-02-10
- Earliest claimed: 2003-06-30
- Inventors: Neil Stahl; George Yancopoulos; Margaret Karow; Eric Smith
- Web page: https://patentgrep.com/patent/US20050032175A1

## CPC

- C12N 15/62: DNA sequences coding for fusion proteins
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/244: {Interleukins [IL]}
- C07K 16/248: {IL-6}
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/10: Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

High affinity fusion proteins capable of binding and inhibiting the activity of soluble, interacting proteins (“SIPs”) are described. In specific embodiments the fusion proteins are multimers, preferably dimers, of SIP-specific fusion polypeptides which comprise SIP binding domains derived from SIP targets and/or anti-SIP immunoglobulin domains, as well as multimerizing components.

## Claims

### Claim 1

An isolated nucleic acid encoding a SIP-specific fusion polypeptide, wherein the fusion polypeptide comprises:
(a) one or more components which comprise a SIP binding domain of a SIP target (TBD);
(b) one or more components which comprise a SIP binding domain of an immunoglobulin (IBD); and
(c) a multimerizing component (M) capable of multimerizing with a multimerizing component on another fusion polypeptide to form a multimer of the fusion polypeptides.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the multimerizing component comprises a constant region(s) of an immunoglobulin or derivative thereof.

### Claim 3 (depends on 2)

The isolated nucleic acid of claim 2, wherein the multimerizing component is selected from the group consisting of the Fc domain of IgG, the Fc domain of the heavy chain of IgG, the Fc domain of the light chain of IgG, and the heavy chain CH2 and CH3 constant regions.

### Claim 4 (depends on 1)

The isolated nucleic acid of claim 1, wherein the IBD is selected from the group consisting of a heavy chain variable domain, a light chain variable domain and an ScFv.

### Claim 5 (depends on 1)

The isolated nucleic acid of claim 1, wherein the SIP-specific fusion polypeptide component arrangements are selected from the group consisting of (TBD)x-(IBD)y-M; (TBD)x-M-(IBD)y; (IBD)x-(TBD)y-M; (IBD)y-M-(TBD)x, M-(IBD)y-(TBD)x, and M-(TBD)x-(IBD)y, wherein TBD is a SIP target binding domain, IBD is an immunoglobulin-derived SIP-binding domain, M is a multimerizing component, and x≧1 and y≧1.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A fusion polypeptide encoded by the nucleic acid of any of claims 1 to 5.

### Claim 7 (depends on 6)

A trapbody comprising two of the fusion polypeptides of claim 6.

### Claim 8

An isolated nucleic acid encoding a SIP-specific fusion polypeptide, wherein the fusion polypeptide comprises:
(a) two or more components which comprise a SIP binding domain of an immunoglobulin (IBD); and
(b) a multimerizing (M) component.

### Claim 9 (depends on 8)

The isolated nucleic acid of claim 8, wherein the fusion polypeptide comprises IBD′-IBD″-M, wherein IBD′ and IBD″ are directed to different epitopes of the same SIP.

### Claim 10 (depends on 8)

The isolated nucleic acid of claim 8, wherein the SIP is a cytokine.

### Claim 11 (depends on 10)

The isolated nucleic acid of claim 10, wherein the SIP target is a specificity-determining component of a cytokine receptor or a signaling component of a cytokine receptor.

### Claim 12 (depends on 11)

The isolated nucleic acid of claim 11, wherein the cytokine is selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-13, IL-15, IL-18, granulocyte macrophage colony stimulating factor, oncostatin M, leukemia inhibitory factor, ciliary neurotrophic factor, MIF, interferon gamma, and cardiotrophin-1.

### Claim 13 (depends on 8, 9, 10, 11, 12)

A fusion polypeptide encoded by the nucleic acid molecule of any of claims 8 to 12.

### Claim 14 (depends on 13)

A trapbody which is a dimer comprising two of the fusion polypeptides of claim 13.

### Claim 15 (depends on 1, 8)

A method of producing a SIP-specific fusion polypeptide, comprising culturing a host cell transfected with a vector comprising the nucleic acid of claim 1 or 8, under conditions suitable for expression of the protein from the host cell, and recovering the fusion protein so produced.

### Claim 16

An isolated nucleic acid encoding (i) a VL CDR selected from the group consisting of SEQ ID NOs:27-32, 43-48, 59-64, 75-80, 91-96 and 107-112, and (i) a VH CDR selected from the group consisting of SEQ ID NOs:19-24, 35-40, 51-56, 67-72, 83-88, and 99-104.

### Claim 17 (depends on 16)

An IL-6-specific antibody or antibody fragment, comprising at least one CDR of claim 16.

### Claim 18 (depends on 16)

An IL-6-specific fusion polypeptide comprising two IL-6-specific immunoglobulin domains and a multimerizing component, wherein each immunoglobulin domain comprises at least one CDR of claim 16.

### Claim 19 (depends on 18)

The IL-6-specific fusion polypeptide of claim 18, wherein at least one immunoglobulin domain is humanized.

### Claim 20 (depends on 18, 19)

A trapbody comprising two IL-6-specific fusion polypeptides of claim 18 or claim 19.

### Claim 21

A trapbody, comprising two fusion polypeptides and capable of binding a soluble protein (SIP), wherein each fusion polypeptide comprises IBD′-IBD″-M, wherein IBD′ and IBD″ are specific to different epitopes of the same SIP, and the trapbody exhibits at least a five-fold increase in affinity relative to a dimer composed of two fusion polypeptides each having a single IBD and a multimerizing component.

### Claim 22

A human IL-6-specific trapbody, comprising IBD-IBD-M, wherein each IBD comprise at least one CDR sequence selected from the group consisting of SEQ ID NOs:19-24, 27-32, 35-40, 43-48, 51-56, 59-64, 67-72, 75-80, 83-88, 91-96, 99-104 and 107-112.

### Claim 23 (depends on 22)

The IL-6-specific trapbody of claim 22, wherein each IBD comprises (i) at least one VL CDR selected from the group consisting of SEQ ID NOs:27-32, 43-48, 59-64, 75-80, 91-96 and 107-112, and (i) at least one VH CDR selected from the group consisting of SEQ ID NOs:19-24, 35-40, 51-56, 67-72, 83-88, and 99-104.

### Claim 24

An antibody heavy chain or heavy chain fragment, comprising one or more of CDR1, CDR2 and CDR3, wherein (i) CDR1 is selected from the group consisting of SEQ ID NO:19, 22, 35, 38, 51, 54, 67, 70, 83, 86, 99 and 102; (ii) CDR2 is selected from the group consisting of SEQ ID NO: 20, 23, 36, 39, 52, 55, 68, 71, 84, 87, 100 and 103; and (iii) CDR3 is selected from the group consisting of SEQ ID NO: 21, 24, 37, 40, 53, 56, 69, 72, 85, 88, 101 and 104.

### Claim 25 (depends on 24)

The antibody heavy chain or heavy chain fragment of claim 24 which is humanized.

### Claim 26

An antibody light chain or light chain fragment, comprising one or more of CDR1, CDR2 and CDR3, wherein (i) CDR1 is selected from the group consisting of SEQ ID NO: 27, 30, 43, 46, 59, 62, 75, 78, 91, 94, 107 and 110; (ii) CDR2 is selected from the group consisting of SEQ ID NO: 28, 31, 44, 47, 60, 63, 76, 79, 92, 95, 108, and 111; and (iii) CDR3 is selected from the group consisting of SEQ ID NO: 29, 32, 45, 48, 61, 64, 77, 80, 93, 96, 109 and 112.

### Claim 27 (depends on 26)

The antibody light chain or light chain fragment of claim 26 which is humanized.

### Claim 28 (depends on 24, 26)

An antibody or antibody fragment, comprising the heavy chain or heavy chain fragment of claim 24 and the light chain or light chain fragment of claim 26.

### Claim 29 (depends on 28)

The antibody or antibody fragment of claim 28 which is humanized.
